Rachel Lebovic1, Natalie Pearce2, Laura Lacey3, James Xenakis4, Cassidy B Faircloth5, Patrick Thompson6. 1. Department of Pharmacy Services, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan. 2. UNC at Chapel Hill Eshelman School of Pharmacy/United Therapeutics, Chapel Hill, North Carolina. 3. Carolinas Healthcare System North East, Charlotte, North Carolina. 4. Department of Biostatistics and Gillings School of Public Health, University of North Carolina, Chapel Hill, North Carolina. 5. Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina. 6. University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
Abstract
BACKGROUND: Increased toxicities have been identified with higher doses of pegaspargase (PEG-ASP) in adults. This has led to routine use of a dose cap of 3,750 IU for adult acute lymphoblastic leukemia (ALL) patients in most institutions. In pediatric ALL patients, PEG-ASP is not capped. There is concern at our institution that larger doses may result in increased rates of adverse effects and that increased monitoring may be warranted in pediatric patients receiving doses greater than 3,750 IU. The objective of this study is to quantify the difference in the rates of PEG-ASP-associated adverse events between pediatric patients who received doses greater than 3,750 IU and less than or equal to 3,750 IU. METHODS: Retrospective chart review of patients 1-21 years old with pre-B-cell ALL who received PEG-ASP between 2007 and 2014 at an academic medical center. RESULTS: Of 183 patients included in the analysis, 24 received PEG-ASP doses higher than 3,750 IU and 159 received doses less than or equal to 3,750 IU. The incidence of venous thromboembolism (VTE) was significantly higher for patients in the group that received more than 3,750 IU compared with those who received 3,750 IU or less (20.8 vs. 1.89%, respectively; P = 0.0011). The incidence of pancreatitis (P = 0.0306) and hyperglycemia (P = 0.0089) were also higher in the group that received more than 3,750 IU. CONCLUSIONS: PEG-ASP doses higher than 3,750 IU are associated with higher rates of VTE, pancreatitis, and hyperglycemia in pediatric patients with pre-B-cell ALL. Patients receiving more than 3,750 IU should have increased monitoring, and larger, multicenter trials are needed to determine if monitoring, VTE prophylaxis, and potential dose capping recommendations should be added to clinical trial protocols.
BACKGROUND: Increased toxicities have been identified with higher doses of pegaspargase (PEG-ASP) in adults. This has led to routine use of a dose cap of 3,750 IU for adult acute lymphoblastic leukemia (ALL) patients in most institutions. In pediatric ALL patients, PEG-ASP is not capped. There is concern at our institution that larger doses may result in increased rates of adverse effects and that increased monitoring may be warranted in pediatric patients receiving doses greater than 3,750 IU. The objective of this study is to quantify the difference in the rates of PEG-ASP-associated adverse events between pediatric patients who received doses greater than 3,750 IU and less than or equal to 3,750 IU. METHODS: Retrospective chart review of patients 1-21 years old with pre-B-cell ALL who received PEG-ASP between 2007 and 2014 at an academic medical center. RESULTS: Of 183 patients included in the analysis, 24 received PEG-ASP doses higher than 3,750 IU and 159 received doses less than or equal to 3,750 IU. The incidence of venous thromboembolism (VTE) was significantly higher for patients in the group that received more than 3,750 IU compared with those who received 3,750 IU or less (20.8 vs. 1.89%, respectively; P = 0.0011). The incidence of pancreatitis (P = 0.0306) and hyperglycemia (P = 0.0089) were also higher in the group that received more than 3,750 IU. CONCLUSIONS:PEG-ASP doses higher than 3,750 IU are associated with higher rates of VTE, pancreatitis, and hyperglycemia in pediatric patients with pre-B-cell ALL. Patients receiving more than 3,750 IU should have increased monitoring, and larger, multicenter trials are needed to determine if monitoring, VTE prophylaxis, and potential dose capping recommendations should be added to clinical trial protocols.
Authors: Wai-Kin Chan; Thomas D Horvath; Lin Tan; Todd Link; Karine G Harutyunyan; Michael A Pontikos; Andriy Anishkin; Di Du; Leona A Martin; Eric Yin; Susan B Rempe; Sergei Sukharev; Marina Konopleva; John N Weinstein; Philip L Lorenzi Journal: Mol Cancer Ther Date: 2019-06-17 Impact factor: 6.261
Authors: Sarah M Kashanian; Noa G Holtzman; Ciera L Patzke; Jonathan Cornu; Alison Duffy; Madhurima Koka; Sandrine Niyongere; Vu H Duong; Maria R Baer; Jummai Apata; Farin Kamangar; Ashkan Emadi Journal: Cancer Chemother Pharmacol Date: 2021-03-07 Impact factor: 3.333
Authors: Saman K Hashmi; Shoba A Navai; Tiffany M Chambers; Michael E Scheurer; M John Hicks; Rachel E Rau; Maria M Gramatges Journal: Pediatr Blood Cancer Date: 2019-11-17 Impact factor: 3.167